Early Access — free while we kick the tires
Michael A Metzger
Chief Executive Officer
Director
Officer
Latest: Syndax Pharmaceuticals Inc CEO selling · July 2026
2 filings analyzed
·
1 company
·
Latest 2026-07-09
Never miss a filing from Michael A Metzger
Watch this insider and we'll alert you the moment they file — at any company.
Activity
July 2026
SNDX CEO Michael Metzger sold 32.4K shares at $24.24 via scheduled 10b5-1 plan; holds 484.8K post-sale
CEO Michael A Metzger executed a scheduled sale of 32,375 shares at $24.24 on 2026-07-08 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 517.2K to 484.8K shares (-6.3%). The transaction was automatic, not discretionary, eliminating timing as a factor for interpretation. Syndax is unprofitable (net income of -$42.7M in the latest quarter) with a $2.2B market cap, though it posted robust annual revenue growth of +627.8%. The stock has appreciated 40.4% over the past 30 days and trades at 2.9% below its 52-week high of $25.59. The sale occurred under a locked-in schedule, so it reflects neither conviction nor concern about current valuation or near-term prospects.
September 2025
157,307 shares
$2,582,021
CEO Michael A Metzger sold 157,307 shares of SNDX at $16.41 on 2025-09-08 ($2.6M) via pre-arranged 10b5-1 plan
CEO Michael A Metzger executed a scheduled sale of 157,307 shares under a pre-arranged 10b5-1 trading plan adopted on 2025-09-10, reducing his holdings by 34.5% from 455,968 to 298,661 shares. The sale proceeds totaled $2,582,021.37 at $16.41 per share. Because this transaction is part of a pre-established trading plan rather than discretionary trading, the timing and price reflect the automatic execution schedule, not current market judgment. The significant reduction in insider holdings warrants investor monitoring to understand whether prior planned diversification, compensation structure changes, or other corporate factors drove the plan's adoption.